



PROGRAMME

Version 4 (SUBJECT TO ALTERATION)

Wednesday 19th October

FLEMING ROOM

| Session Time | Abstract Number | Session Topic & Presenter |
|--------------|-----------------|---------------------------|
|--------------|-----------------|---------------------------|

08.30 [Welcome / Housekeeping](#)

PELVIC TUMOURS 1

| | | |
|-------|---------|--|
| 08.35 | 111 | Percutaneous Cementoplasty for the Pelvis in Bone Metastasis: 12-Year Experience. <i>Dr Jong Woong Park, National Cancer Center, Goyang, Korea, Republic of</i> |
| 08.43 | 117 | Outcomes of anterior minimally invasive (robotic & laproscopic) dissection of malignant bone tumours of the pelvis and sacrum: A multidisciplinary surgical approach. <i>Dr Pramod Chinder, HCG Hospital, Bangalore, India</i> |
| 08.51 | 74 | A 6-Point Protocol In Management Of Pelvic Bone And Soft Tissue Tumors. <i>Dr Amar Kamat, HCG HOSPITAL, BANGALORE, India Single Institute Outcome From India</i> |
| 08.59 | 129 tbc | Complications of surgical management of bony tumors of the obturator framework. (Enneking Zone 3). <i>Speaker TBC</i> |
| 09.07 | | Questions |
| 09.17 | 284 | New technique of allograft acetabulum reconstruction due to malignant bone tumours. <i>Prof Oleg Vyrva , Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine</i> |

- 09.25 240 Mid to long-term clinical results of the LUMiC® prosthesis for reconstruction after periacetabular tumor resection. *Dr Richard Evenhuis, Leiden University Medical Center, Leiden, Netherlands*
- 09.33 182 Pelvic ring reconstruction with the non vascularized fibular free graft following internal hemipelvectomy. *Prof Toru Akiyama, Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan*
- 09.41 164 Is Reconstruction Necessary Following Iliosacral Resection? A Comparison of Outcomes from Two Tertiary Sarcoma Centers. *Dr Jay Wunder / Mr Anthony Griffin, Division of Orthopaedic Surgery, Department of Surgery, University of Toronto Musculoskeletal Oncology Unit, Sinai Health System, Toronto, Canada*

09.49 Questions

09.59 DEBATE: HANGING HIP OR RECONSTRUCTION?

10.15 REFRESHMENTS

PELVIC TUMOURS IN 3D

- 10.45 116 Three-dimensional (3D) printed guides for malignant bone tumours: Institutional experience of 127 cases and work-flow to design ideal guides for complex resections of pelvis and sacrum. *Dr Pramod Chinder, HCG Hospital, Bangalore, India*
- 10.53 169 Reconstructions surgery with custom-made 3D-printed pelvic prosthesis due to malignancy or benign bone tumors involving the acetabulum. Single-center retrospective cohort study with clinical follow-up including patients from 2014 to 2020. *Ms Müjgan Yilmaz, Rigshospitalet, Copenhagen, Denmark*
- 11.01 255 Clinical and biomechanical considerations to develop a custom made 3D printed pelvic reconstruction - a collaborative work between surgeons and engineers. *Dr Alba Gonzalez Alvarez, Universidad Carlos III de Madrid, Madrid, Spain*
- 11.09 323 Application of 3D printing in Guided Pelvic Resections: Experience from 2 Tertiary Referral Centers in the UK. *Mr M A Siddiqi, Nuffield Orthopaedic Center, Oxford, United Kingdom & RNOH, UK*
- 11.17 Questions
- 11.27 172 Does Patient Specific Instrumentation (PSI) improve local control when operating pelvic bone tumors : a controlled multicenter trial. *Prof Francois Guin, Centre Léon Bérard, Lyon, France*
- 11.35 245 NEW INCENTIVES AND PITFALLS IN PATIENT-SPECIFIC PELVIC IMPLANTS MADE BY ADDITIVE MANUFACTURING. *Dr André Olivier, Vergelegen Mediclinic, Somerset West, South Africa*
- 11.43 217 High accuracy of positioning custom 3-dimensional printed pelvic implants in tumour and total hip revision surgery: a multicentre cohort study of 35 patients. *Dr Demien Broekhuis LUMC, Leiden, Netherlands*
- 11.51 337 The use of navigation vs custom-made saw jigs in computer assisted pelvic resection and reconstruction. What is better? *Prof Pietro Ruggieri, Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy, Padova, Italy*
- 11.59 Questions

| | | |
|-------|--|--|
| 12.10 | DEBATE: IS IT NEGLIGENCE NOT TO USE NAVIGATION FOR PELVIC RESECTION? | |
| 12.30 | LUNCH | |
| | INVITED LECTURE | |
| 13.30 | | Getting It Right First Time in Sarcoma. UK National GIRFT Project <i>Prof Tim Briggs, CBE</i> |
| | COMPLICATIONS | |
| 13.50 | 294 | What is the complication rate in total femur replacement? Case series. <i>Dr Marisa Valentini, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria</i> |
| 13.55 | 32 | The effect of implant type on re-operation rates following endoprosthetic reconstruction surgery. <i>Ms Victoria Giglio, McMaster University, Hamilton, Canada</i> |
| 14.00 | 247 | Failures and management experience in proximal femur tumor endoprostheses. <i>Dr Osman Emre Aycan, Baltalimani Bone Disease Training and Education Hospital, Istanbul, Turkey</i> |
| 14.05 | 269 | Wound complications in Operations of the Thigh & Pelvis: Outcomes from the London Sarcoma Service's Bone and Soft tissue Sarcoma Team. <i>Ms Eliza Davison, Royal Free London NHS Foundation Trust, London, United Kingdom</i> |
| 14.10 | | Questions |
| 14.20 | EXTREME ORTHOPAEDIC SYMPOSIUM <i>Chair: Will Aston</i> Invited complex case discussions | |
| 15.00 | EMSOS STUDIES - UPDATE | |
| 15.30 | EMSOS Closing Ceremony and Prize Giving | |
| 16.00 | REFRESHMENTS | |

Wednesday 19th October

WHITTLE ROOM

| Session Time | Abstract Number | Session Topic & Presenter |
|--------------|-----------------|---------------------------|
|--------------|-----------------|---------------------------|

08.30 **Welcome / Housekeeping**

ADVANCES IN DIAGNOSIS, STAGING AND SURVEILLANCE OF SARCOMAS

| | | |
|-------|-----|---|
| 08.35 | 23 | Liquid biopsy for monitoring paediatric Ewing sarcoma patients. <i>Prof Andreas Leithner, Department of Orthopedics and Trauma, Medical University of Graz, Graz, Austria</i> |
| 08.40 | 86 | A Review of 1884 Core Biopsies In Orthopedic Oncology - A Single Institute Experience. <i>Dr Anto Gopurathingal, HCG hospital, Bangalore, India</i> |
| 08.45 | 244 | Sensitivity, specificity and predictive values of tru-cut biopsy in primary localized myxoid liposarcoma of the extremities. <i>Dr Gianmarco Tuzzato, Unit of 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy</i> |
| 08.50 | 173 | Study of the spatial heterogeneity of the microenvironment of osteosarcoma by innovative histopathological and mechano-biological approaches: role in resistance to treatment. <i>Prof Anne Gomez-Brouchet, Institut Universitaire du Cancer de Toulouse, Toulouse, France</i> |
| 08.55 | 100 | Soft tissue solitary fibrous tumor: is histopathological pattern sufficient for defining prognosis or do we need further biomolecular insights and markers? <i>Dr Guido Scoccianti, Careggi University Hospital - Department of Orthopaedic Oncology, Firenze, Italy</i> |
| 09.00 | | Questions |
| 09.10 | 312 | SURFACE OSTEOSARCOMAS. A RECLASSIFICATION OF THE LESIONS. <i>Dr habib nouri , private hospital, tunis, Tunisia,</i> |
| 09.15 | 110 | 2b or not 2b :The periosteum is the question. <i>Prof Lee Jeys,Royal Orthopaedic Hospital, Birmingham, United Kingdom</i> |
| 09.20 | 271 | Myxoid liposarcoma 10-year surveillance programme. <i>Mr Ethan Caruana, Manchester University NHS Foundation Trust, Manchester, United Kingdom</i> |
| 09.25 | 56 | The Surveillance After Extremity Tumor Surgery (SAFETY) International Randomized Controlled Trial. <i>Michelle Ghert, McMaster Hospital, Hamilton, Canada</i> |

09.30 222 Non-invasive detection of soft tissue sarcoma using volatile organic compounds in exhaled breath: a pilot study. *Prof Michiel Van de Sande, Leiden University Medical Center, Leiden, Netherlands*

09.35 Questions

INVITED LECTURE

09.45 Medico-legal aspects of sarcomas
Prof Rob Grimer

10.15 REFRESHMENTS

INNOVATION AND FUTURE PERSPECTIVES

10.45 103 Primitive Study on a 3D Preoperative Planning System for Bone and Soft Tissue Tumors Using a Virtual Reality Game Console. *Dr Munenori Watanuki, JR Sendai Hospital, Sendai, Japan*

10.52 299 Automated 3D reconstruction and biomechanical adjustment on virtual 3D models for complex hip joint reconstruction pre-surgery planning. *Mr Simonas Utkus, Republican Vilnius University Hospital, Vilnius, Lithuania*

10.59 289 3D-printing and computer navigation in preoperative planning and surgical management of soft tissue sarcoma. *Dr Juan P. Zumarraga, Hospital Metropolitano, Quito, Ecuador*

11.06 291 3D virtual reality simulation for musculoskeletal tumors: reconstruction and simulated surgery. A preliminary 15 case study. *Dr Juan P Zumarraga, Universidad San Francisco de Quito, Quito, Ecuador*

11.13 115 Planning and executing surgery using 3D printing technology - with 3D designing, modeling and rapid prototyping; end-to-end tips from an Engineer's perspective in an orthopedic oncology team. *Mr Kumar Sukrit, The Yellow Ribbon (Manfrini & PHO Institute of Sarcoma Research), Bangalore, India*

11.20 Questions

11.30 189 Using augmented reality for intraoperative guidance during needles placement for cryoablation of Desmoid tumors. *Dr Eran Golden, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel*

11.37 161 Phototherapy in the Treatment of Malignant Bone Tumors. *Prof Frank Traub, Department of Orthopedic and Traumatology, University Medical Center, Mainz, Germany*

11.44 278 SARCOSIGHT: A Randomised-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care. *Dr Marcus Brookes, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom*

11.51 250 Indications and clinical outcomes of oncological patients treated with carbon-fibre plates: an international multi-institutional study. *Mr Zeger Rijs, Leiden University Medical Center, Leiden, Netherlands*

11.58 Questions

12.10 Close of session

12.30 **LUNCH**

13.30 **INTERACTIVE EPR INFECTION SYMPOSIUM**

Chair: Tariq Azamgarhi, RNOH

- Pre-workshop poll – to establish current practice
- 13.40 98 Patient and Surgical Risk Factors for Surgical Site Infection in Lower Extremity Oncologic Endoprosthetic Reconstruction: A Secondary Analysis of the PARITY Trial Data. *Dr David Slawaska-Eng, McMaster University, Hamilton, Canada*
- 13.50 91 Risk factors for all-cause early re-operations in patients undergoing tumor resection and endoprosthetic reconstruction: a secondary analysis from the PARITY trial. *Dr Joseph Kendal, University of California, Los Angeles, Santa Monica, USA*
- 14.00 232 Silver coated tumour prostheses in oncologic indications : about 56 cases with 53 months follow up. *Dr Fabrice Fiorenza, Department of orthopaedic surgery-Dupuytren Teaching Hospital, Limoges, France*
- 14.10 27 Silver-coated megaprotheses (PorAg®) can be protective against reinfection in the treatment of oncologic prosthesis infection. *Dr Andrea Sambri. IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, Italy*
- 14.20 239 The infected megaprosthesis: treatment strategies, results. *Dr Alexander Klein, Orthopaedic Oncology; Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 14.30 *Dr Simon Warren - Infection specialist's perspective*
- 14.40 *Dr Andrej Trampuz, Berlin, Germany - Strategies in bone infection. What else is there besides antibiotics and silver. TBC*
- 14.50 *Tariq Azamgarhi - Pharmacist's perspective*
- 15.00 *Mr Craig Gerrand - Surgeon's perspective*
- 15.10 Live poll - What are the next research questions?

Close of Session

CONTINUED OVERPAGE

Wednesday 19th October

GIELGUD ROOM

| Session Time | Abstract Number | Session Topic & Presenter |
|--------------|-----------------|---------------------------|
|--------------|-----------------|---------------------------|

08.30 **Welcome / Housekeeping**

METASTATIC BONE DISEASE 1

| | | |
|-------|-----|---|
| 08.35 | 93 | A patient-specific fracture risk assessment tool for femoral bone metastases; using the BOne Strength (BOS) score in clinical practice. <i>Dr Florieke Eggermont, Orthopaedic Research Lab, Radboud university medical center, Nijmegen, Netherlands</i> |
| 08.40 | 207 | Predicting proximal femoral pathologic fractures from digitally reconstructed radiographs using deep learning in advanced cancer patients. <i>Dr Yong-Suk Lee, Department of Orthopaedic Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of</i> |
| 08.45 | 57 | External validation of the 2013-SPRING model for survival prediction in surgically treated patients with metastases to the appendicular skeleton. <i>Dr Maria Anna Smolle, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria</i> |
| 08.50 | 72 | Development of a scoring system for survival following surgery in metastatic bone disease. <i>Dr Rachel Baumber, Royal National Orthopaedic Hospital, London, United Kingdom</i> |
| 09.55 | 5 | Clinical Outcome Differences in the Treatment of Impending Versus Completed Pathological Long-Bone Fractures. <i>Dr Olivier Groot, Massachusetts General Hospital, Boston, USA</i> |
| 08.55 | 7 | The preoperative machine learning algorithm for extremity metastatic disease can predict 90-day and 1-year survival: two international external validations. <i>Dr Olivier Groot, Massachusetts General Hospital, Boston, USA</i> |
| 09.00 | | Questions |
| 09.10 | 165 | Trends in surgical treatment of long bones diaphysis metastases among orthopedic surgeons. <i>Mr Dawid Ciechanowicz, Department of Paediatric Orthopaedics and Oncology, Pomeranian Medical University, Szczecin, Poland</i> |
| 09.15 | 65 | Patient survival after resection of skeletal metastases and endoprosthetic reconstruction: A nation-wide cohort study with a single decision-making oncological institution. <i>Prof Blaž Mavčič, University Medical Centre Ljubljana, Department of Orthopaedic Surgery, Ljubljana, Slovenia</i> |
| 09.20 | 248 | Survival and surgical outcomes in patients with tibial metastases: a dual-center study. <i>Dr Tommaso Greco, Department of Orthopaedics and Trauma Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy</i> |

- 09.25 85 OUTCOMES OF INTERCALARY ENDOPROSTHESES AS A TREATMENT FOR METASTASES IN THE DIAPHYSIS OF FEMUR AND HUMERUS. *Dr Michal Mahdal, First Department of Orthopedic Surgery, St. Anne's University Hospital, Brno, Czech Republic*
- 09.30 12 Sustained inflammation and deranged cytokine expression impair healing of pathological fractures in the presence of breast cancer cells. *Prof Francis Lee, Yale, New Haven, USA*
- 09.35 6 Body composition predictors of mortality in patients undergoing surgery for long bone metastases. *Dr Olivier Groot, Massachusetts General Hospital, Boston, USA*
- 09.40 Questions

INVITED LECTURE

- 09.50 11 A minimally invasive 4-dimensional AORIF procedure for periacetabular osteolytic metastases in a prospective cohort of 55 patients. *Prof Francis Lee, Yale, New Haven, USA*

10.05 REFRESHMENTS

METASTATIC BONE DISEASE 2

- 10.45 92 Cancer ablation and focal fixation for focal osteolytic metastatic lesions in the proximal or distal femur: One long-implant fits all? or Personalized focal AORIF oncologic fixation? *Prof Francis Lee, Yale University, New Haven, USA*
- 10.50 80 Comparison of Carbon Fiber and Titanium Intramedullary Nails In Orthopaedic Oncology. *Dr Caleb Yeung, Massachusetts General Hospital, Boston, USA*
- 10.55 147 Do cemented standard-length femoral stems have enough longevity for the pathological fractures of the femoral neck with metastatic lesions? A retrospective study. *Dr Pakjai Tuntarattanapong, Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand*
- 11.00 179 Megaprosthesis for Metastatic Bone Disease- A Comparative Analysis. *Dr Joachim Thorkildsen, Oslo Univeristy Hospital, Oslo, Norway*
- 11.05 306 Options and Challenges when treating Bone Metastatic Renal Cell Carcinoma. *Dr Mihnea Ioan Gabriel Popa, University Emergency Hospital, Bucharest, Romania*
- 11.10 228 Surgical management options for long-bone metastasis. *Dr Bogdan Stefan Cretu, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania*
- 11.15 Questions

KEYNOTE PRESENTATION

- 11.30 UK National Guidelines for Treating metastatic Bone Disease: The British Orthopaedic Association Standard for Trauma (BOAST)
Profesor Rob Ashford, Professor of Orthopaedic Oncology, University of Leicester
President British Orthopaedic Oncology Society (BOOS)

11.45

INTERACTIVE SESSION ON MBD

Case Discussions

12.30

LUNCH

13.30

BOOS INTERACTIVE SESSION

UK Sarcoma Fellowships - Training the Next Generation

Collabotaive Research - How and Who?

BOOS Diploma - How did it go?

National EPR Database

Can we agree which data/metrics collect for Primary Bone Sarcoma?

14.20

BOOS AGM

Close of Session

Wednesday 19th October

OLIVIER ROOM 2nd Floor

12.30

LUNCH - Euro Ewings Consortium

Local Therapy Networking Lunch (Closed Meeting - EEC members only)

14.30

Close of Session